Seattle Genetics (ticker: SGEN, exchange: NASDAQ Global Market (.O))
News Release -
Seattle Genetics Initiates Phase I Clinical Trial of SGN-10 in Combination with Taxotere for Patients with Carcinoma
Bothell, WA - September 19, 2000 - Seattle Genetics, Inc. announced the initiation of a second phase I clinical trial with its single-chain immunotoxin, SGN-10. This study will evaluate SGN-10 in combination with TaxotereŽ for patients with advanced carcinoma. Aventis Pharmaceuticals, the manufacturer of TaxotereŽ, is co-funding the trial costs and is providing TaxotereŽ drug product. TaxotereŽ is an effective chemotherapeutic agent that is widely used in the treatment of many solid tumor types. Separately, a single-agent phase I study of SGN-10 in patients with carcinoma is ongoing.
The study opened at the Lombardi Cancer Institute at Georgetown University Medical Center in Washington, D.C. with other sites to be added later. "We are pleased to be testing the combination of SGN-10 and TaxotereŽ in cancer patients," stated Dr. Amy Sing, Senior Director of Medical Affairs for Seattle Genetics. "In preclinical models, the combination of SGN-10 and taxanes was extremely effective."
Seattle Genetics, Inc. is a privately held biotechnology company focused on developing novel therapeutics to enhance the survival of cancer patients. The Company's research and development initiatives use monoclonal antibody-based therapeutics encompassing four technology platforms: single-chain immunotoxins (SCIT), antibody-drug conjugates (ADC), monoclonal antibodies (mAbs), and antibody-directed enzyme prodrug therapy (ADEPT). Seattle Genetics has two drugs currently in three clinical trials, including SGN-15, an ADC being tested in a phase I/II clinical trial in carcinoma patients, two in late-stage development and several lead agents undergoing preclinical testing. One of the late-stage development drug candidates is being developed through an alliance with Genentech, Inc.